The company intends to use the funds to support the development and scale-up of its VECTOR� platform, expansion of its AI-enabled mRNA design and automated high-throughput screening capabilities, and development of clinical-grade manufacturing capabilities.

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

Slovak Academy of Sciences Dubravska cesta 9
Bratislava, 845 05
SK

Phone

Undisclosed

Website

www.sensible.bio

Email Address

[email protected]

Overview

Developer of a cell-based platform designed to produce high-quality mRNA for the next generation of mRNA therapeutics and vaccines. The company offers cost-efficient and scalable mRNA production through principles of cell engineering, computational biology, and precision fermentation, enabling the pharmaceutical industry to produce high-quality mRNA for the next generation of mRNA therapeutics and vaccines.

Profile

Social Media

Sensible Biotechnologies Company Twitter Account

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Miroslav Gasparek

Chief Scientific Officer

Marian Kupculak

Browse more venture capital transactions:

Prev: 10/6/2026: RougeTx venture capital transaction
Next: 10/6/2026: Zeroset venture capital transaction

Share this article

Where The Data Comes From

Our team works diligently to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary